Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab long-term safety in CVD (FOURIER OLE)
NCT02867813Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2016
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of evolocumab in dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), sponsored by Amgen. Started Sep 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
dyslipidemiaatherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT02867813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867813.